HDFC MF and ADIA Lead Major ₹777 Crore Block Deal in Corona Remedies

A massive liquidity event unfolded in the pharmaceutical sector as Sepia Investments and Anchor Partners offloaded significant stakes in Corona Remedies Limited. This high-value block deal attracted a heavy-weight lineup of domestic and international institutional investors, signaling strong confidence in the company's long-term prospects.

Breakdown of the Mega Divestment

On June 17, 2026, the stock exchange witnessed a substantial transfer of ownership in Corona Remedies. The primary seller, Sepia Investments, divested 43,28,943 shares at a price of ₹1,730 per share, amounting to approximately ₹748.9 crore.

Adding to this exit, Anchor Partners also offloaded 1,61,861 shares at the same price point of ₹1,730, contributing an additional ₹28 crore to the transaction. In total, these two sellers collectively exited positions worth roughly ₹776.9 crore in the pharmaceutical major.

HDFC Mutual Fund Dominates the Buy Side

The transaction saw participation from twelve distinct institutional buyers, with HDFC Mutual Fund emerging as the most aggressive acquirer. By purchasing 24,50,000 shares, HDFC MF invested approximately ₹423.9 crore, effectively absorbing more than half of the total deal value.

The buy-side appetite was further bolstered by several other major players:

• Aditya Birla Sun Life Mutual Fund: Acquired 4,90,000 shares worth ₹84.8 crore.
• Aberdeen Asian Smaller Companies Investment Trust Plc: Bought 4,50,868 shares for roughly ₹78 crore.
• Invesco Mutual Fund: Picked up 2,89,017 shares valued at ₹50 crore.
• Aberdeen Standard Sicav I: Acquired 2,74,132 shares worth ₹47.4 crore.

Global Institutional Interest in Corona Remedies

Beyond domestic mutual funds, the deal highlighted significant interest from global sovereign wealth and international asset management firms. The Abu Dhabi Investment Authority (ADIA) participated in the deal, acquiring 39,130 shares worth approximately ₹6.8 crore.

其他值得关注的国际参与者还包括投资了 2.51 亿卢比的 WhiteOak Capital Mutual Fund，以及投入了 2.57 亿卢比的 India Acorn ICAV - Ashoka WhiteOak Emerging Markets Equity Fund。该交易还包括来自 Kotak Mahindra Mutual Fund（2.8 亿卢比）、Factory Mutual Insurance Company（1900 万卢比）以及 TCW White Oak Emerging Markets Equity Fund（330 万卢比）的小额注资，展示了机构对该股票估值的广泛共识。

核心要点

• 大规模流动性事件： Sepia Investments 和 Anchor Partners 的总减持额在每股 1,730 卢比的价格下达到了约 77.69 亿卢比。
• HDFC MF 的主导地位： HDFC Mutual Fund 是基石买家，投资额为 42.39 亿卢比，占交易总额的 50% 以上。
• 多元化的投资者结构： 该交易汇集了印度本土共同基金与 ADIA 和 Aberdeen 等全球巨头，表明机构对 Corona Remedies 具有强烈的信任。